Benchmarking weakly-supervised deep learning pipelines for whole slide classification in computational pathology.

Artificial intelligence Computational pathology Convolutional neural networks Multiple-Instance Learning Vision transformers Weakly-supervised deep learning

Journal

Medical image analysis
ISSN: 1361-8423
Titre abrégé: Med Image Anal
Pays: Netherlands
ID NLM: 9713490

Informations de publication

Date de publication:
07 2022
Historique:
received: 20 08 2021
revised: 07 04 2022
accepted: 03 05 2022
pubmed: 20 5 2022
medline: 3 6 2022
entrez: 19 5 2022
Statut: ppublish

Résumé

Artificial intelligence (AI) can extract visual information from histopathological slides and yield biological insight and clinical biomarkers. Whole slide images are cut into thousands of tiles and classification problems are often weakly-supervised: the ground truth is only known for the slide, not for every single tile. In classical weakly-supervised analysis pipelines, all tiles inherit the slide label while in multiple-instance learning (MIL), only bags of tiles inherit the label. However, it is still unclear how these widely used but markedly different approaches perform relative to each other. We implemented and systematically compared six methods in six clinically relevant end-to-end prediction tasks using data from N=2980 patients for training with rigorous external validation. We tested three classical weakly-supervised approaches with convolutional neural networks and vision transformers (ViT) and three MIL-based approaches with and without an additional attention module. Our results empirically demonstrate that histological tumor subtyping of renal cell carcinoma is an easy task in which all approaches achieve an area under the receiver operating curve (AUROC) of above 0.9. In contrast, we report significant performance differences for clinically relevant tasks of mutation prediction in colorectal, gastric, and bladder cancer. In these mutation prediction tasks, classical weakly-supervised workflows outperformed MIL-based weakly-supervised methods for mutation prediction, which is surprising given their simplicity. This shows that new end-to-end image analysis pipelines in computational pathology should be compared to classical weakly-supervised methods. Also, these findings motivate the development of new methods which combine the elegant assumptions of MIL with the empirically observed higher performance of classical weakly-supervised approaches. We make all source codes publicly available at https://github.com/KatherLab/HIA, allowing easy application of all methods to any similar task.

Identifiants

pubmed: 35588568
pii: S1361-8415(22)00121-9
doi: 10.1016/j.media.2022.102474
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102474

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest JNK declares consulting services for Owkin, France and Panakeia, UK. TJB reports owning a company that develops mobile apps, outside the scope of the submitted work (Smart Health Heidelberg GmbH, Handschuhsheimer Landstr. 9/1, 69120 Heidelberg). No other potential conflicts of interest are reported by any of the authors.

Auteurs

Narmin Ghaffari Laleh (N)

Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.

Hannah Sophie Muti (HS)

Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.

Chiara Maria Lavinia Loeffler (CML)

Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.

Amelie Echle (A)

Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.

Oliver Lester Saldanha (OL)

Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.

Faisal Mahmood (F)

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Ming Y Lu (MY)

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Christian Trautwein (C)

Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.

Rupert Langer (R)

Institute of Pathology and Molecular Pathology, Kepler University Hospital, Johannes Kepler University Linz, Linz, Austria.

Bastian Dislich (B)

Institute of Pathology, University of Bern, Switzerland.

Roman D Buelow (RD)

Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany.

Heike Irmgard Grabsch (HI)

Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands.; Division of Pathology and Data Analytics, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.

Hermann Brenner (H)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany; Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Jenny Chang-Claude (J)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Cancer Epidemiology Group, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Elizabeth Alwers (E)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Titus J Brinker (TJ)

Digital Biomarkers for Oncology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Firas Khader (F)

Department of Radiology, University Hospital RWTH Aachen, Aachen, Germany.

Daniel Truhn (D)

Department of Radiology, University Hospital RWTH Aachen, Aachen, Germany.

Nadine T Gaisa (NT)

Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany.

Peter Boor (P)

Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany.

Michael Hoffmeister (M)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Volkmar Schulz (V)

Department of Physics of Molecular Imaging Systems, Experimental Molecular Imaging, RWTH Aachen University, Aachen, Germany; Fraunhofer Institute for Digital Medicine MEVIS, Bremen, Germany; Comprehensive Diagnostic Center Aachen (CDCA), University Hospital Aachen, Aachen, Germany; Hyperion Hybrid Imaging Systems GmbH, Aachen, Germany.

Jakob Nikolas Kather (JN)

Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany; Division of Pathology and Data Analytics, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK; Else Kroener Fresenius Center for Digital Health, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany. Electronic address: jkather@ukaachen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH